Stock Markets July 30, 2026 07:34 AM

Align Technology Shares Drop After Revenue Guide Miss, Scanner Business Slump and One-Time Tax Charge

Company raises buyback range and plans board changes, but a softer Q3 guide and a VAT liability weigh on investor sentiment

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
ALGN

Align Technology stock fell sharply in pre-market trading after the company issued third-quarter 2026 revenue guidance below analyst expectations alongside quarterly results. While quarterly revenue and adjusted earnings per share were broadly in line and clear aligner volume hit a record, weakness in Systems and Services, a £37.5 million (reported as $37.5 million) UK VAT liability charge and a lower-than-expected Q3 outlook dominated investor focus. Management increased its 2026 share repurchase authorization and said it will add three independent directors following engagement with an activist investor.

Align Technology Shares Drop After Revenue Guide Miss, Scanner Business Slump and One-Time Tax Charge
ALGN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Align issued Q3 2026 worldwide revenue guidance of $1.00 billion to $1.02 billion, below the rough analyst midpoint range of about $1.02 billion to $1.05 billion.
  • Q2 adjusted EPS was $2.64 and revenue was $1.06 billion, up 4.3% year-over-year, with record clear aligner unit volumes of 691,800.
  • Systems and Services revenue fell 10.8% year-over-year to $185.3 million due to a shift toward lower-cost scanner configurations and leasing programs; GAAP net income was hit by a $37.5 million UK VAT liability charge.

Shares of Align Technology declined 5.3% in pre-open trading after the maker of Invisalign clear aligners issued a third-quarter 2026 revenue outlook that came in below analysts' consensus. The guidance, released with the company's Wednesday evening earnings report, put Q3 worldwide revenue in a $1.00 billion to $1.02 billion range - under the rough analyst midpoint range of about $1.02 billion to $1.05 billion.

The quarterly results themselves delivered several mixed signals. Adjusted earnings per share for the quarter were $2.64, narrowly topping estimates, and total revenue reached $1.06 billion - a 4.3% increase year-over-year. The company also reported record clear aligner case volumes of 691,800 units, underscoring demand for its core product line.

However, parts of the business showed notable pressure. Systems and Services revenue fell 10.8% year-over-year, declining to $185.3 million. Management attributed that decline to a strategic shift toward lower-cost scanner configurations and expanded leasing programs. GAAP net income was further reduced by a $37.5 million UK VAT liability charge disclosed in the quarter.

Following the results, Needham analysts maintained a Hold rating on the shares. In parallel with the earnings release, Align said it expanded its 2026 share repurchase program to a range of $400 million to $500 million after engagement with activist investor Elliott Investment Management. The company also announced plans to appoint three new independent directors to its board.

The market backdrop offered no clear reason for the single-name weakness: the S&P 500, Dow Jones and Nasdaq were trading higher on the same day, indicating the pullback in Align stock was driven by company-specific developments tied to the earnings reaction rather than a broad market sell-off.

In summary, the combination of a softer-than-expected Q3 revenue guide, ongoing weakness in the scanner-related business, the one-time VAT charge and the prospect of additional restructuring costs weighed on investor sentiment. Those headwinds overshadowed the quarter's record aligner volumes and an expanded buyback program, prompting the pre-market decline.

Risks

  • Softer-than-expected revenue guidance for Q3 could pressure the stock further - impacts technology and healthcare equipment suppliers.
  • Ongoing weakness in the scanner business and shifts to lower-cost configurations may limit near-term margin recovery - impacts medical device and diagnostic hardware vendors.
  • One-time tax and liability charges such as the $37.5 million UK VAT assessment, and announced restructuring costs, create earnings volatility and balance-sheet uncertainty - affects investors focused on corporate earnings and cash flow stability.

More from Stock Markets

Colliers International Shares Jump After Q2 2026 Beat and Unchanged Guidance Jul 30, 2026 Mastercard Q2 Profit Climbs as Steady Consumer Spending Keeps Transactions Rising Jul 30, 2026 Nuclear Concentration or Broad-Spectrum Capacity - Choosing Between CEG and VST for AI-Era Power Jul 30, 2026 Leonardo DRS Pops After Strong Q2 Results and Raft Acquisition Announcement Jul 30, 2026 Mastercard Shares Jump After Strong Q2 Results and Supportive Analyst Calls Jul 30, 2026